Skip to main content

Table 2 Efficacy and safety data from the three trials comparing rivaroxaban with the European enoxaparin dose as thromboprophylaxis following elective total hip or knee replacement surgery [2224]

From: Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants

 

10 mg rivaroxaban initiated post-surgery

40 mg enoxaparin initiated 12 h pre-surgery

RECORD1 trial (hip replacement)

Total VTE and all-cause mortality (primary efficacy end-point)

18/1595 (1.1%)

58/1558 (3.7%)

Major bleeding

6/2209 (0.3%)

2/2224 (0.1%)

RECORD2 trial (hip replacement)*

Total VTE and all-cause mortality (primary efficacy end-point)

17/864 (2.0%)

81/869 (9.3%)

Major bleeding

1/1228 (0.08%)

1/1229 (0.08%)

RECORD3 trial (knee replacement)

Total VTE and all-cause mortality (primary efficacy end-point)

79/824 (9.6%)

166/878 (18.9%)

Major bleeding

7/1220 (0.6%)

6/1239 (0.5%)

  1. VTE venous thromboembolism
  2. *In RECORD2, rivaroxaban was given for 31 to 39 days, while enoxaparin was given for 10 to 14 days